Commonwealth Equity Services LLC Purchases Shares of 44,500 Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Commonwealth Equity Services LLC purchased a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 44,500 shares of the company’s stock, valued at approximately $64,000.

Several other institutional investors have also made changes to their positions in TNYA. Synovus Financial Corp bought a new stake in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $28,000. Spire Wealth Management acquired a new position in shares of Tenaya Therapeutics in the fourth quarter valued at approximately $53,000. SG Americas Securities LLC lifted its holdings in shares of Tenaya Therapeutics by 61.9% during the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after purchasing an additional 15,777 shares during the period. Atticus Wealth Management LLC increased its stake in shares of Tenaya Therapeutics by 56.3% in the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock valued at $68,000 after buying an additional 17,199 shares during the period. Finally, XTX Topco Ltd lifted its position in shares of Tenaya Therapeutics by 51.2% in the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares during the period. 90.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TNYA has been the subject of a number of research analyst reports. Canaccord Genuity Group lowered their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research note on Monday, March 31st. Chardan Capital reduced their price objective on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. Finally, Morgan Stanley reduced their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $6.25.

Insider Activity

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the transaction, the insider now owns 49,313,559 shares in the company, valued at $34,519,491.30. This represents a 262.62 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 19,621 shares of company stock valued at $10,595. 32.76% of the stock is currently owned by insiders.

Tenaya Therapeutics Trading Up 12.0 %

Tenaya Therapeutics stock opened at $0.49 on Friday. The firm has a market capitalization of $43.17 million, a PE ratio of -0.34 and a beta of 2.98. Tenaya Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $4.96. The firm’s 50 day simple moving average is $0.74 and its 200 day simple moving average is $1.56.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Research analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.